P-selectin-deficient mice to study pathophysiology of sickle cell disease

Blood Adv. 2020 Jan 28;4(2):266-273. doi: 10.1182/bloodadvances.2019000603.

Margaret F Bennewitz^{1

2}, Egemen Tutuncuoglu¹, Shweta Gudapati¹, Tomasz Brzoska^{1

3}, Simon C Watkins⁴, Satdarshan P Monga⁵, Tirthadipa Pradhan-Sundd^{1

3

6}, Prithu Sundd^{1

3

7

8}

¹ Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA.
² Department of Chemical and Biomedical Engineering, West Virginia University, Morgantown, WV.
³ Sickle Cell Center of Excellence.
⁴ Center for Biologic Imaging.
⁵ Division of Experimental Pathology.
⁶ Division of Hematology and Oncology, and.
⁷ Division of Pulmonary Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA; and.
⁸ Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA.

Abstract

P-selectin–deficient SCD mice are protected from lung vaso-occlusion.
P-selectin–deficient SCD mice will be useful in assessing the benefits of anti–P-selectin therapy in diverse complications of SCD.